About Event
Defining Novel Targets and Validating Endpoints, to Accelerate First-in-Class Therapeutics for Dry AMD & Geographic Atrophy
Returning in a fully digital format, the 6th Dry AMD & Geographic Atrophy Therapeutics Summit offers three dynamic days of cutting-edge content and curated networking, connecting global stakeholders across biotech, pharma, academia, and investment.
The program delivers cross-functional insights for advancing therapies from early discovery to late-stage development, featuring expert-led panels, clinical case studies, investor discussions, and regulatory workshops.
Attendees will gain practical strategies on trial design, emerging endpoints, delivery technologies, and funding. With interactive sessions and virtual networking, this summit offers an unmatched opportunity to collaborate and accelerate dry AMD and GA programs without geographic barriers.
Why Join Us This Year:
Discuss funding strategies with healthcare investors from PENG Life Science Ventures and ExSight Ventures, and independent strategists to learn what data, milestones, and positioning matter most in today’s competitive development landscape
Get updates on the latest clinical progress and development strategies from biopharma leaders including Apellis, Ocugen, and Clearside Biomedical to gain practical takeaways to refine your own developments and anticipate where the field is moving next
Define global regulatory expectations and learn how to de-risk early-stage programs by aligning study design, endpoints, and imaging strategies with FDA and EMA feedback, guided by regulatory consultants with proven approval experience in dry AMD
Explore novel mechanisms beyond complement including ferroptosis, mitochondrial rescue, and RPE regeneration, with insights from VisgenX and PulseSight Therapeutics to identify differentiated therapeutic approaches and evaluate which next-gen strategies are gaining traction in the clinic
Integrate AI, imaging biomarkers, and functional endpoints into your early-phase trial planning with insights from leading academics and members of the International Retinal Imaging Society to increase efficiency and align with evolving regulatory standards
Who Will You Meet?
The 6th Dry AMD & Geographic Atrophy Therapeutics Summit brings together a global community of 40+ experts in clinical development, translational research, regulatory, and business development professionals from biotech, pharma, and academia advancing novel therapies for dry AMD and Geographic Atrophy.
Connect with senior biopharma leaders from Apellis, Boehringer Ingelheim, AbbVie, Genentech, Sanofi, Novartis, Aviceda, ONL Therapeutics
What Your Peers Have to Say:
“This was my first Hanson-Wade conference/meeting. I did not know what to expect, and my expectations were exceeded. Particularly, I was surprised at how forthcoming speakers were with sharing their company's data and collaboration.”
Director - Chemistry, Manufacturing & Controls, Gene & Cell Therapy & Early Discovery, Rejuvitas
“The meeting presented a great opportunity for academics to interact with pharma and see where we really stand on getting drugs to patients. I think there was a lot of great discussions.”
Assistant Professor, Johns Hopkins University
"Focused meeting with willingness of participants to share ideas and experience."
Chief Scientific Officer, Akari Therapeutics
“Excellent knowledgeable speakers, interactive, wide range of industry from start-ups to strategies, discussion of challenges not just successes including regulatory perspectives. The basic scientists and clinicians added great flavor.”
Associate Director, Ophthalmology, Dompe
“The almost complete coverage of assets under development and the forthrightness of the presenting speakers.”
Founder & Chief Executive Officer, Drusolv Therapeutics